NeuroStar® Advanced Therapy Reaches Monumental Milestone of 1.7 Million Treatments in the US
Non-drug, non-invasive NeuroStar has become a mainstream option for depression patients, and is now covered by most insurance companies and available in 49 states
MALVERN, Pa., May 5, 2018 /PRNewswire/ — NeuroStar® Advanced Therapy, the established leader in transcranial magnetic stimulation (TMS), announced today that more than 1.7 million treatments have been delivered to approximately 50,000 adult depression patients in the United States. Clinical outcomes for 1,000 patients in the NeuroStar Outcomes Registry will be presented at the 2018 American Psychiatric Association Annual Meeting (APA) inNew York, May 5-9, 2018, highlighting how the company continues to transform the transcranial magnetic stimulation category.
5.5 million adults in the United States treated for depression do not achieve remission with antidepressant medication.1,2,3 By hitting this treatment milestone, NeuroStar demonstrates the need that these depression patients have for an alternative option that gives hope and breaks barriers in the process. In addition to reaching this treatment milestone, NeuroStar recently rolled out the first national television advertising campaign for transcranial magnetic stimulation. This ad campaign is part of the company’s investment to educate consumers on this innovative treatment across the U.S.
“There is no greater feeling than to hit this treatment milestone and know that we’re continuing to positively impact the lives of our patients and those dealing with depression,” said Chris Thatcher, President and CEO of Neuronetics, Inc. “We know from STAR*D that remission rates decline with each antidepressant attempt, moving from 27.5% with a first-line medication treatment down to 6.9% with three prior treatment failures.4,5 As a non-drug option with expanded insurance coverage and availability, NeuroStar Advanced Therapy is another tool doctors have at their disposal to transform lives and help patients combat depression.”
NeuroStar is also leading the way with clinical research, launching its own adolescent trial, spearheading the largest depression outcomes registry to date, and supporting investigator-initiated trials to develop new research for transcranial magnetic stimulation. NeuroStar will present clinical outcomes and key information at APA’s Annual Meeting, including:
Poster Session on Outcomes Registry
NeuroStar’s depression outcomes registry, which was launched to further investigate and understand the use of transcranial magnetic stimulation in a clinical setting, has exceeded 1,000 patients in the United States. NeuroStar’s registry is projected to grow to 6,000 patients by 2019 — making it one of the largest registries for depression treatment. (Monday, May 7 from 10 a.m. – 12:00 p.m.)
Product Theater on Adolescent Depression
Dr. Ahmed Elmaadawi will present “The Pathway from the Past to the Future in Treatment of Adolescent Depression — TMS as an Option” and discuss the initial clinical findings. Dr. Elmaadawi is an investigator in NeuroStar’s randomized, controlled clinical trial to evaluate the acute and long-term effectiveness of the therapy in adolescent and young adult patients ages 12 to 21. (Monday, May 7 at 2 p.m. ET)
“Meet the Experts” Sessions
NeuroStar Advanced Therapy providers will share the latest TMS updates and their experiences with the NeuroStar treatment as part of a panel at the NeuroStar booth. (Sunday, May 6 from 11 a.m. – 12 p.m. and 2 – 3 p.m. ET; Monday, May 7 from 11 a.m. – 12 p.m. and 3 – 4 p.m. ET; Tuesday, May 8 from 11 a.m. to 12 p.m. ET)
Ahmed Elmaadawi, MD, at Behavioral Medical Group Behavioral Health in South Bend, IN
Annie Farley, LPN, Co-owner at TMS Wellness Center in St. Louis, MO
Kalyan Dandala, MD, Chief Medical Officer at Associated Behavioral Health Care in Seattle, WA